1. Home
  2. |Insights
  3. |ABA - Section of Litigation - Regional CLE Workshop: Current Issues in Pharmaceutical and Medical Device Litigation

ABA - Section of Litigation - Regional CLE Workshop: Current Issues in Pharmaceutical and Medical Device Litigation

Event | 11.12.09, 12:00 AM UTC - 12:00 AM UTC

This one day Regional CLE Workshop will cover the latest in pharmaceutical and medical device litigation. There will be panel discussions with leaders in the field. Topics will include: nanotechnology; updates on preemption; developments in the federal laws governing pharmaceutical and medical device manufacturers; supplier quality and outsourcing risks; and much more!

Steve Niedelman is speaking on "Supplier Quality and Outsourcing Risks" and Heather Hodges is a moderator on that panel.

This panel will discuss the potential liability and regulatory risks faced by manufacturers when buying materials from suppliers or outsourcing manufacturing functions -- and steps that can be taken to mitigate those risks. Participants will receive an an overview of issues relating to supplier quality and managing the litigation/regulatory risk associated with outsourcing functions such as sub-assembly, packaging-labeling, sterilization and manufacture of component parts. Our panelists will demonstrate how to develop an effective, efficient risk-based audit program to assure incoming quality and reduce potential risk such as damage to corporate reputation or increased liability and litigation costs associated with defective products.

Click for the event brochure [PDF]

For more information, please visit these areas: Product Risk Management, Mass Tort, Product, and Consumer Litigation

Insights

Event | 12.04.25

ACI 30th Annual Conference on Drug & Medical Device Litigation

Dan Campbell with Speak on the panel "Mastering MDL Case Management: What Proposed Rule 16.1 Really Means for Consolidated Litigation."
Rule 16.1 attempts to guide early case management in MDLs, impacting litigation pace and costs. Permissive language like “should” instead of “must”, could lead to inconsistent applications. This panel will explore the rule’s anticipated impact and implications for procedures.